Clinical Trials Browser

Phase 1/2 × Has results × tislelizumab × Clear all

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Phase 1/2 Completed

53 enrolled 17 charts

Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT03379259 2024-10-26

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Terminated

39 enrolled 29 charts

Other solid neoplasm

Advanced Solid Tumors

NCT03941873 2024-10-26

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Phase 1/2 Completed

111 enrolled 22 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT04068519 2024-10-26

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Phase 1/2 Completed

300 enrolled 23 charts

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody